Levo-Methasan

Levomethadone Hydrochloride, the active ingredient in Levo-Methasan, is an opioid presented as a tablet for oral use. It is employed to manage opioid dependence and to provide analgesia for chronic pain in adult patients. GNH USA supplies Levo-Methasan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levomethadone, an opioid agonist, is used in the management of opioid dependence and chronic pain. - Opioid dependence: suppresses withdrawal symptoms and supports maintenance therapy. - Chronic pain: provides analgesia for severe, persistent pain conditions. - Opioid substitution therapy: serves as an alternative to methadone in substitution programs.

Levomethadone may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Constipation: reduced bowel motility. - Drowsiness: increased sleepiness or fatigue. - Dry mouth: reduced salivation. - Sweating: excessive perspiration. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, potentially life‑threatening. - QT interval prolongation: risk of cardiac arrhythmia. - Severe hypotension: marked drop in blood pressure. - Seizures: rare convulsive episodes. - Allergic reactions: rash, itching, or anaphylaxis. - Adrenal insufficiency: impaired cortisol production.

Levomethadone requires careful clinical monitoring to minimize risks associated with opioid therapy. - Assess opioid tolerance: evaluate patient history before initiating therapy. - Monitor respiratory function: watch for signs of depression, especially after dose changes. - Avoid concomitant CNS depressants: increased risk of profound sedation and respiratory depression. - Use caution in hepatic impairment: dose adjustment may be necessary. - Pregnancy and lactation: limited data; weigh benefits against potential risks. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Levomethadone can interact with several drug classes, altering its safety profile or efficacy.

Major Interactions (Avoid): - Concomitant CNS depressants (e.g., benzodiazepines): risk of profound sedation and respiratory depression. - Monoamine oxidase inhibitors: may precipitate severe opioid toxicity. - QT‑prolonging agents (e.g., certain antiarrhythmics): additive risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may increase levomethadone plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Alcohol: enhances sedative and respiratory‑depressant effects.